EXPO Jumps 24% in a Month as JP Morgan Lifts Target to $100

Exponent, Inc. enters November with its sharpest one-month rally in recent memory, up 24% to $80.26, and a fresh analyst upgrade giving bulls a concrete upside target to argue around.

The most immediate catalyst came on October 30, when JP Morgan raised its price target on EXPO to $100 from $90, maintaining its Overweight rating. That puts the mean Street target at $90.67, still below the current JP Morgan level, and implies roughly 13% upside from Friday's close. UBS sits at the other end of the debate, holding a Neutral rating with a $72 target set back in July, roughly 10% below where the stock trades today. The bull case rests on Exponent's position in engineering and litigation consulting, where demand tied to infrastructure complexity and regulatory scrutiny tends to be durable. Bears point to valuation: the trailing P/E has expanded to 29.4x, up more than 5 points over the past month, and price-to-book has moved to 9.5x. The EV/EBITDA of 18.2x is not cheap for a mid-cap consultancy. Factor scores reinforce the split: the dividend score ranks in the 83rd percentile, a signal of financial stability, but sector momentum sits in just the 6th percentile and forward EPS momentum over 30 days ranks 12th. The stock has recovered strongly, but the scorecard reads as quality, not momentum.

Positioning in the lending market poses no meaningful pressure on either side. Short interest is 6.1% of free float, up modestly through October, with the daily estimate running around 3.0 million shares. That is not a crowded short. Borrow availability is extraordinarily loose at roughly 2,700% of short interest, meaning there are nearly 27 shares available to lend for every one currently borrowed. Cost to borrow is just 0.47%, up 14% on the week but still firmly in the low single digits. The ORTEX short score of 45.8 sits near the midpoint of its range and has barely moved across the past two weeks. None of this suggests short sellers are leaning hard against the rally, but neither are they retreating.

Options positioning leans put-heavy but without alarm. The put/call ratio is running at 5.49, well above its 20-day average of 4.09, though the z-score of 0.85 puts that reading less than one standard deviation from normal. The ratio has been structurally elevated for weeks, so the current reading reflects EXPO's habitual skew toward protective positioning rather than a sudden defensive shift. The 52-week range for the PCR runs from 0.02 to 11.97, so a reading of 5.49 sits in the middle of that band.

Retail attention has picked up noticeably alongside the rally. Wikipedia pageview data, tracked by the Wikimedia Foundation and scored by ORTEX's alt data layer against Exponent's own 90-day history, shows an attention z-score of 1.85. That is a meaningful uptick in visibility, consistent with a stock that has just moved 24% in a month and received a high-profile analyst target raise. It is a colour indicator of elevated awareness, not a financial signal.

Insider activity over the past 90 days tells a mildly cautious story. Net activity amounts to a sale of roughly 3,260 shares worth about $210,000, driven almost entirely by CEO Catherine Corrigan's option exercises paired with planned 10b5-1 sales. The sales are pre-scheduled, so they carry limited informational weight as a directional signal. A single open-market purchase by a Group Vice President in September, worth around $12,600, is the only discretionary buying on the record.

On the institutional side, BlackRock holds 13% of shares, with Kayne Anderson Rudnick and two Vanguard vehicles collectively accounting for another 20%. No Schedule 13D activist is on the register. Conestoga Capital Advisors trimmed its stake slightly in its most recent 13G amendment. These are passive positions and long-term holders, not a catalyst in themselves, but the concentrated and stable shareholder base limits the likelihood of large forced selling into strength.

The next earnings event is scheduled for February 4, 2027. The most recent quarterly print, reported October 29, produced a 4.1% one-day gain, consistent with the stock's pattern of modest positive reactions to results. With 96 days to the next report, the key question between now and then is whether the valuation expansion that the October rally delivered can find earnings growth to catch up with it.